Escitalopram AbZ

Quick links

Choose a section

Quick links to important sections

Advertisements
Advertisements

Overview of Escitalopram AbZ

Property Description
Active Ingredient Escitalopram (S-enantiomer)
Form Film-coated tablet, oral solution
Pharmacological Class Selective Serotonin Reuptake Inhibitor (SSRI)
General Purpose Supporting mood regulation and enhancing emotional balance
Origin Synthetic, single-component product

What Type of Medicine is Escitalopram AbZ?

Escitalopram AbZ is a prescription-only pharmaceutical preparation classified primarily as an antidepressant and a psychoanaleptic agent. The substance belongs to the class of Selective Serotonin Reuptake Inhibitors (SSRIs). This classification signifies a focused action on the central nervous system, identifying it as a modern synthetic agent used to support emotional and mood balance. Escitalopram is a member of the SSRI family.

Active Ingredient and Unique Composition

The sole active ingredient in this medication is Escitalopram (INN: Escitalopram), which is the active component of the formulation by AbZ Pharma GmbH. This specific active substance is the purified S-enantiomer, a feature that distinguishes it from the older, less selective, racemic mixture known as citalopram. This characteristic reflects the compound's high degree of selectivity for its intended biological target. The medication is commonly supplied for oral administration in the form of a film-coated tablet, a single-component product designed for convenient and consistent use.

General Purpose of an SSRI Antidepressant

The general purpose of this medicine is to promote the stabilization of mood and enhance emotional resilience by influencing neurochemical activity. Escitalopram achieves this by its primary mechanism: the potent and highly selective inhibition of the reuptake of the neurotransmitter serotonin (5-HT) by nerve cells. By blocking this reabsorption, the concentration of serotonin available to transmit signals is increased, which helps to modulate and balance the pathways responsible for mood and anxiety patterns within the brain. The substance is used for stabilizing emotional states for individuals facing persistent low mood or heightened anxiety.

Advertisements

What side effects are possible with Escitalopram AbZ?

Possible side effects and safety information

The safety profile of Escitalopram AbZ is defined by regulatory classifications of adverse reactions based on their frequency of occurrence, as documented in official government sources.

Officially Documented Adverse Reactions and Frequencies

The most frequently documented effects are classified as Very Common (geq 10% incidence), which include headache and nausea.

Adverse reactions classified as Common (occurring in 1% to 10% of patients) affect several body systems:

  • Nervous/Psychiatric: Insomnia (difficulty sleeping), somnolence (drowsiness), dizziness, and decreased libido.
  • Gastrointestinal: Dry mouth, diarrhea, and constipation.
  • General: Fatigue and increased sweating.

Serious Adverse Reactions and Safety Patterns

Regulatory agencies require specific attention to serious reactions and safety concerns, which include:

  • Risk of Suicidality: Antidepressant medications carry a boxed warning regarding an increased risk of suicidal thoughts and behaviors in young adults (up to age 24).
  • Serotonin Syndrome: The occurrence of this potentially severe condition is documented, with the risk elevated with concomitant use of other serotonergic drugs.
  • Cardiovascular Risks: QT interval prolongation is a documented dose-dependent risk for heart rhythm abnormalities.
  • Metabolic: The development of hyponatremia (low sodium levels in the blood) is a documented risk.

Contextual and Population-Specific Safety Notes

The timing of certain effects is noted: a temporary increase in anxiety symptoms may occur at the beginning of treatment. The risk of suicidality is generally greatest during early treatment and periods following dose changes.

Safety notes specific to certain patient groups are defined, including an elevated risk for hyponatremia in older adults. Caution and typically a lower maximum daily dose are advised for patients with hepatic impairment.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose presentations involving escitalopram primarily affect the central nervous system (CNS), cardiovascular system, and gastrointestinal (GI) tract. Reported symptoms include drowsiness, coma, seizures, sinus tachycardia (fast heart rate), QTc prolongation (a heart rhythm abnormality), arrhythmia, and hypotension (low blood pressure).

In rare instances, more severe cardiac events such as torsade de pointes have been observed. Other potential manifestations are tremor, agitation, dizziness, nausea, vomiting, and increased sweating (diaphoresis).

Overdose Risk Factor Description (Authoritative Sources)
Co-Ingestion Fatal outcomes are reported mainly when escitalopram is taken with other medicines, especially those that increase serotonin levels, such as MAO inhibitors.
Cardiac Risk Overdose carries a risk of QTc prolongation. Individuals with pre-existing heart disease, electrolyte abnormalities (e.g., low potassium or magnesium), or advanced age may be at greater risk.

Immediate medical attention is required for any suspected overdose. Emergency treatment is supportive and symptomatic: a patent airway must be established and maintained, and adequate oxygenation and ventilation ensured. Cardiac and vital signs should be closely monitored. Gastrointestinal decontamination, such as the administration of activated charcoal, should be considered as soon as possible after ingestion.

Advertisements

Therapeutic Uses of Escitalopram AbZ

Escitalopram AbZ is commonly used to help manage symptoms across multiple domains of emotional and psychological distress, offering supportive relief. In situations where patients experience Major Depressive Disorder (MDD) and Generalized Anxiety Disorder (GAD), the medication is considered relevant and applied across domains where additional symptomatic support is needed.

Easing Symptomatic Distress

The medication is used for managing conditions presenting with acute episodes, including persistent low mood and loss of pleasure, chronic excessive worry, sudden panic attacks, severe social fear, and recurrent obsessive-compulsive symptoms. The medication plays a role in managing symptomatic distress and symptom clusters that may become intense or disruptive. This assists with maintaining functional stability when symptoms interfere with routine activities.

Quick Fact: Relief for Persistent Worry

Escitalopram AbZ is commonly used across conditions characterized by periods of heightened symptoms and contributes to easing the overall symptom load associated with chronic anxiety.

Advertisements

Eligibility and Restrictions for Use

Escitalopram AbZ eligibility is defined by official regulatory documentation, establishing specific populations that are permitted to use the medicine and those that are absolutely prohibited.

Contraindicated Populations (Must Not Use)

Use of this medicine is absolutely prohibited in patients with known hypersensitivity to escitalopram or its ingredients. It is also contraindicated for patients who are currently taking Monoamine Oxidase Inhibitors (MAOIs), the medicine pimozide, or those with known QT-interval prolongation or congenital long QT syndrome.

Age- and Condition-Based Restrictions

Population Group Official Eligibility Status
Children/Adolescents (<18 yrs) Not recommended (EU/SmPC); Approved for specific indications for ages ge 7 or ge 12 (US/FDA).
Older Adults (ge 65 years) Conditional Use; recommended maximum daily dosage is typically lower than for younger adults.
Hepatic Impairment Restricted; the recommended maximum dose is limited, typically to 10 mg/day.
Severe Renal Impairment Caution advised; use is not established due to insufficient data.
Pregnancy Conditional Use; use only if the potential benefit justifies the potential risk.
Lactation Not recommended; caution should be exercised as the drug is excreted into human milk.

Use also requires specific caution in patients with a history of seizures, mania, or those with an increased risk of bleeding.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Contraindicated Combinations

Escitalopram AbZ must not be used concomitantly with certain medicines due to the risk of severe, potentially life-threatening interactions:

  • Monoamine Oxidase Inhibitors (MAOIs): Including irreversible MAOIs, linezolid (an antibiotic with MAOI activity), and intravenous methylene blue. A washout period of at least 14 days is required when switching between escitalopram and an MAOI.
  • Pimozide: This antipsychotic is contraindicated due to an increased risk of heart rhythm abnormalities (QT-prolongation).
  • QT-prolonging medicines: Any medication known to prolong the QT-interval should not be combined with escitalopram, as this increases the risk of ventricular arrhythmias.

Cautionary Combinations

Concomitant use of escitalopram with the following requires careful monitoring and may necessitate dose adjustments or avoidance:

  • Other Serotonergic Agents: Medicines such as triptans, fentanyl, tramadol, lithium, tryptophan, and the herbal remedy St. John's Wort may increase the risk of serotonin syndrome.
  • Agents Affecting Bleeding: Non-steroidal anti-inflammatory drugs (NSAIDs), aspirin, and oral anticoagulants (e.g., warfarin) may increase the risk of abnormal bleeding due to escitalopram's effect on platelet function.
  • CYP Enzyme Inhibitors/Inducers: Medicines that affect the liver enzymes CYP2C19 and CYP3A4 can alter escitalopram plasma concentrations. Dose adjustment may be necessary, particularly in elderly patients or those known to be CYP2C19 poor metabolisers.
  • Alcohol: Consumption of alcohol is advised against due to the potential for enhanced central nervous system effects.
Advertisements

Mechanism of Action

Selective Serotonin Transporter Blockade

Escitalopram's core mechanism is the selective inhibition of the Serotonin Transporter (SERT), the presynaptic protein responsible for clearing serotonin (5-HT) from the synaptic cleft. This action immediately prevents the reabsorption of 5-HT back into the neuron, thereby increasing the concentration of the neurotransmitter available to activate postsynaptic receptors. This singular, targeted molecular intervention is the essential first step in the drug’s cascade, contributing to its defined receptor binding profile.


Time-Dependent Neural Adaption

While the blockade of SERT is immediate, the full functional effect relies on a delayed, adaptive cascade, typically requiring several weeks. Sustained high synaptic 5-HT levels eventually cause the desensitization of inhibitory 5-HT1A autoreceptors, effectively removing a biological brake on 5-HT release. This chronic, enhanced serotonergic signaling promotes neuroplasticity and the upregulation of Brain-Derived Neurotrophic Factor (BDNF). This neurochemical and structural remodeling supports the maintenance of neural function.


Limbic System Neurotransmitter Rebalance

The cumulative effect of increased serotonin availability and subsequent neural remodeling is concentrated on regulating activity within the limbic system, which is involved in emotional processing. By supporting the restoration of neurochemical equilibrium in these circuits, the mechanism facilitates the modulation of neural responses to stimuli. The resulting modulation of these core pathways establishes a rebalanced state of serotonergic signaling within the central nervous system.

Advertisements

Dosage and Administration Information

How Escitalopram AbZ is Used: Official Guidelines

The administration of Escitalopram is defined by standardized guidelines, which establish a protocol for its use, strictly focused on the route, dose, and frequency.

Instruction Scope Standard Protocol
Route and Frequency The route of administration is oral, prescribed for use once daily.
Standard Adult Dosing The typical starting dose is 10 mg once daily, which may be adjusted to a maximum daily limit of 20 mg.
Dose Titration Interval Any upward dose adjustment must follow a minimum period of at least one week at the previous dose to manage the titration process.
Timing Relative to Food May be taken with or without food, allowing for flexible daily scheduling.
Specific Population Limit The maximum recommended daily dose for older adults (aged 65 years and over) is restricted to 10 mg.

Procedural Structure

The protocol dictates the administration process over time. The medicine is supplied as film-coated tablets and an oral solution, where the latter requires accurate measurement for proper use. The treatment course is typically extended, and the protocol includes a requirement that discontinuation must be accomplished through a gradual dose reduction (tapering) over a period of at least one to two weeks. This procedural requirement is a core component of the long-term administration protocol.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Escitalopram AbZ

Evidence for Use in Major Depressive Disorder (MDD)

Research has explored this medicine's use in individuals experiencing Major Depressive Disorder (MDD). The evidence base primarily consists of Randomized Controlled Trials (RCTs), where this medicine was evaluated against an inactive substance (placebo) and against active-comparator medications. These studies have monitored outcomes related to symptom intensity, using standardized scales over defined short-term time intervals. When evaluated against active-comparator medications, the research describes that differences in measured scale scores were sometimes reported as numerically small.

What remains uncertain is the full picture of outcomes for very long-term treatment (beyond six months to a year). While patterns related to the maintenance of low symptom levels were observed in some studies, data providing insight into outcomes over multiple years are less comprehensive. Findings reported for adolescent patient cohorts (ages 12–17) may also show some inconsistency across various study designs, and data for specific severe patient subgroups are less detailed.

Evidence for Use in Generalized Anxiety Disorder (GAD)

The evidence base for Generalized Anxiety Disorder (GAD) was built using multiple Randomized Controlled Trials (RCTs) against placebo, structured for both short-term acute assessment and for follow-up trials monitoring the rate of symptom return. The key outcomes measured included changes on standardized anxiety severity scales and patient-reported outcomes describing perceived discomfort. Long-term follow-up research has described patterns related to the sustained monitoring of low symptom levels over defined time intervals, with some studies monitoring patients for up to 76 weeks.

One documented limitation of the early GAD research is that certain study protocols were structured to exclude patients with severe, co-occurring Major Depressive Disorder, which means the findings reflect a specific population. Furthermore, insights from studies focusing on patients with high degrees of fluctuating or unstable symptoms are less characterized.

Evidence Gaps and Areas for Future Study

Research limitations noted across the studies include that follow-up durations were limited in many pivotal trials, restricting insight into outcomes beyond the short-term. Comparative evidence is lacking for some of the other available treatments, making broad statements about group patterns compared to other medicines difficult. Data for certain groups remain insufficient, especially for patients with highly fluctuating or unstable symptoms or those with complex co-occurring medical conditions. Findings describe group patterns, not personal outcomes, and evidence highlights what is known—and what is still uncertain—about this medicine's use.

Key Studies & References

  1. Escitalopram Bristol Public Assessment Report (EMA Generic Procedure)
  2. ClinicalTrials.gov: An Efficacy and Safety Study of Escitalopram Long-Term Treatment in Major Depressive Disorder With Associated Anxiety Symptoms (NCT01814098)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Escitalopram AbZ (FAQ)

Q: If I miss a dose of Escitalopram AbZ, what should I generally do?

Official patient information describes the general protocol for a missed dose, which involves resuming the schedule or skipping the forgotten dose, depending on the timing relative to the next dose. Regulatory guidance specifies that two doses should never be taken at the same time.


Q: Is it common to feel worse before feeling better when starting Escitalopram AbZ?

It is commonly reported in official safety information that some people may temporarily experience side effects when they first start this medicine. These can include nausea, headache, or a brief increase in anxiety symptoms. This timing is often consistent with the several weeks required for the medicine's full, stable effect to develop.


Q: What are the most commonly reported side effects when first starting this medicine?

According to official regulatory documentation, the most frequently reported side effects (occurring in 10% or more of patients) are headache and nausea. Other effects that are common in the early stages of treatment include fatigue, increased sweating, drowsiness, and difficulty sleeping. These symptoms are part of the medicine's known safety profile.


Q: Can Escitalopram AbZ cause weight gain?

Official product documents indicate that increased appetite is a documented side effect. As a result, changes in body weight, including weight gain, may be observed in some individuals taking this medicine.


Q: Is it possible to become dependent on Escitalopram AbZ?

The medicine is not generally classified in official sources as causing addiction. However, the body does adjust to the medicine’s presence, meaning abrupt stopping can lead to documented discontinuation symptoms. For this reason, regulatory guidelines describe a process of gradual dose reduction, known as tapering, when treatment is to be discontinued.


Q: What are the signs that Escitalopram AbZ is starting to work?

Official information notes that the medicine’s full effect is not immediate and typically requires several weeks due to time-dependent neural adjustments in the brain. Clinical studies monitor for changes related to symptom intensity and overall emotional state as markers of effectiveness.


Q: Is Escitalopram AbZ taken for specific types of panic attacks?

While authorized uses can vary across different regulatory agencies globally, some official bodies include the treatment of Panic Disorder in their approved indications for this medicine.


Q: How long is a typical course of treatment with Escitalopram AbZ?

Treatment for conditions such as Major Depressive Disorder (MDD) is frequently structured to last several months or longer beyond the initial period where symptoms improve. Official guidance describes that the long-term usefulness of the medicine is subject to periodic reassessment by the prescribing professional.


Q: Is Escitalopram AbZ used to treat Obsessive-Compulsive Disorder (OCD)?

Some major government drug agencies, including the European Medicines Agency (EMA), have authorized the use of escitalopram for the treatment of Obsessive-Compulsive Disorder (OCD).


Q: What is the risk of having severe side effects from Escitalopram AbZ?

Regulatory documents classify certain adverse reactions as serious, which generally occur at a low frequency. These include the potential for Serotonin Syndrome, a dose-dependent risk for heart rhythm abnormalities (QT interval prolongation), and a risk of hyponatremia (low sodium levels in the blood). These warnings highlight the need for appropriate clinical consideration during use.


Q: Do I need to take Escitalopram AbZ at the same time every day?

The medicine is intended to be taken just once daily. Official product information notes that it can be taken in the morning or the evening. For consistency in use, the crucial administrative factor is taking the medicine once daily.


Q: Can I drive or operate machinery while taking Escitalopram AbZ?

Regulatory documents contain a specific warning regarding the medicine's potential to interfere with cognitive and motor performance. Official guidance suggests caution regarding operating machinery or driving until the individual knows how the medicine affects their alertness and coordination.


Q: What happens if I take Escitalopram AbZ with cold or flu medicines?

Many over-the-counter cold and flu products contain ingredients that can potentially interact with this medicine. Regulatory guidelines note specific caution regarding products containing Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) due to an increased risk of bleeding. Also, certain cough and cold ingredients may elevate serotonin levels, increasing the risk of serotonergic side effects.


Q: Does Escitalopram AbZ lose its effect over time?

Official research evidence indicates that while there are gaps in the comprehensive data for very long-term use (beyond one year), studies have shown patterns related to the maintenance of low symptom levels in some patients who continue treatment.


Q: What kind of monitoring is typically done when a person is on Escitalpram AbZ?

Regulatory documents describe the monitoring required for certain outcomes, particularly the emergence or worsening of depression or suicidal thoughts/behaviors in young adults. Monitoring also typically involves checking for specific metabolic issues like hyponatremia (low sodium levels), and potentially hepatic and renal function in certain patient groups.


Q: Can Escitalopram AbZ affect my ability to concentrate at work?

Since official documents list potential side effects such as drowsiness and dizziness, and advise that the medicine may impair thinking or motor skills, general caution may be suggested. This is relevant for tasks that require full mental attention and concentration.


Q: Is Escitalopram AbZ meant to be a permanent medication?

Treatment is typically extended, often lasting several months or longer. Official regulatory guidance states that the long-term or continued usefulness of the medicine is subject to periodic reassessment by the prescribing professional.

Advertisements

How should Escitalopram AbZ be stored and disposed of?

Storage and Disposal of Escitalopram AbZ

Official regulatory documents define strict conditions to maintain the stability and safety of Escitalopram AbZ tablets.

Storage Requirements

Condition Regulatory Mandate
Temperature Store below 30°C
Protection Must be protected from light
Container Keep in the original container or packaging
Child Safety Keep out of the sight and reach of children

Disposal Instructions

To prevent environmental contamination, unused or expired Escitalopram AbZ must be handled as regulated pharmaceutical waste. Disposal must be performed in accordance with local requirements, such as taking the product to a pharmacy or government-approved collection point. The product must not be disposed of via household trash or wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Escitalopram AbZ found in:

A-Z Index: